GoodinDS.Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol2014; 122: 455–464.
2.
BeckRWClearyPAAndersonMMJr. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med1992; 326: 581–588.
3.
CzockDKellerFRascheFM. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet2005; 44: 61–98.
4.
HayballPJCoshDGAhernMJ. High dose oral methylprednisolone in patients with rheumatoid arthritis: Pharmacokinetics and clinical response. Eur J Clin Pharmacol1992; 42: 85–88.
5.
RohatagiSBarthJMollmannH. Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol1997; 37: 916–925.
6.
TuckermannJPKleimanAMcPhersonKG. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci2005; 42: 71–104.
7.
HeroldMJMcPhersonKGReichardtHM.Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci2006; 63: 60–72.
8.
LeussinkVIJungSMerschdorfU. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol2001; 58: 91–97.
9.
SchmidtJGoldRSchonrockL. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain2000; 123(Pt 7): 1431–1441.
10.
MorrowSAStoianCADmitrovicJ. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology2004; 63: 1079–1080.
11.
ChatawayJ.Oral versus intravenous steroids in multiple sclerosis relapses—A perennial question?Mult Scler2014; 20: 643–645.
12.
AlamSMKyriakidesTLawdenM. Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry1993; 56: 1219–1220.
13.
Ramo-TelloCGrau-LopezLTintoreM. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler2014; 20: 717–725.
14.
Le PageEVeillardDLaplaudDA. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): A randomised, controlled, double-blind, non-inferiority trial. Lancet2015; 386: 974–981.
15.
SellebjergFFrederiksenJLNielsenPM. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology1998; 51: 529–534.
16.
MetzLMSabudaDHilsdenRJ. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology1999; 53: 2093–2096.
